Written by Jasper Cantrell On Nomvember 18th, 2020, labroots published the article: “Could Targeting the Proteasome be Effective Against Cancer?” Research conducted out of the University of Toyama in Japan says “yes”. The proteosome is a complex protein responsible for the degradation of other cellular proteins that are marked with ubiquitin. In melanoma the upregulation of protein PSMD14, responsible for un-tagging of ubiquitinated proteins, is seen as a primary means for cancer proliferation. In the study conducted at the University of Toyama, scientists conducted a PSMD14 knockout, which subsequently upregulated p21 expression and activated RB. P21 and RB are inhibitor proteins that prevent the cell cycle from progressing, leading to cell death. Therefore, in vitro the upregulation of these proteins leads to impaired melanoma growth. Their study concludes, “Although we identified PSMD14 as a molecular target for melanoma, there is currently no available drug targeting PSMD14. As the disturbance of proteasome function by PSMD14 knockdown may affect melanoma growth, proteasome inhibitors, including bortezomib, may be attractive drugs for melanoma.”
To view the original article, please visit labroots.
Комментарии